Inertial Confinement Fusion Patents: Leaders, Trends & White Space 2026
- Filing has plateaued, not accelerated. The trend runs from 5 filings in 2017 to a 2023 peak of 6, with the 2022 midpoint at 3 — a flat-to-declining curve rather than the exponential growth headline coverage of fusion might suggest.
- G21B dominates but the family spills into medicine. 62 of 92 records sit in G21B (fusion reactors), yet A61K and A61P together account for 18 records — a sign that capsule and radiation techniques are being claimed for therapeutic uses as much as for energy.
- The US leads filing venues by a wide margin. 29 records were filed at the USPTO against 13 at WIPO and 11 at the EPO, with New Zealand and Israel each drawing a handful — a filing geography concentrated far more narrowly than the science itself.
What the ICF patent record actually covers
Inertial confinement fusion patenting sits at the intersection of high-energy laser optics, target capsule design and plasma physics. The search set here is narrow by design — it requires both an ICF-adjacent term and an ignition, compression or implosion term in the same record, which excludes broad laser or plasma filings that never touch target physics. That discipline matters: 62 of the 92 families classify under G21B, the fusion-reactor subclass, but a meaningful share also touch H05H plasma and particle-accelerator claims and, less expectedly, A61K/A61P medicinal and therapeutic classes.
Publication in this data cut runs through mid-2026, and because publication typically lags filing by around eighteen months, the last one to two years of the trend will understate true filing activity. Reading the curve as flat rather than declining is the safer interpretation until later years catch up.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 92-family dataset: how filing volume has moved year over year, and how those families split across IPC subclasses.
A plateau, not a boom
From 5 filings in 2017 to a peak of 6 in 2023, with the 2022 midpoint at 3, the filing curve does not show the acceleration that would signal a technology entering a commercialisation race. It reads as steady, low-volume activity from a small set of committed filers, with publication lag likely understating the most recent one to two years.
G21B carries the core, but the tail is not laser optics
G21B (fusion reactors) accounts for 62 of 92 records, the clear core. H05H (plasma and particle accelerators) follows at 14. The notable pattern is the combined 18 records across A61K and A61P — medicinal preparations and therapeutic activity — which suggests capsule and radiation-delivery concepts developed for ICF are being repurposed or co-filed for medical applications, a crossover worth tracking separately from the energy story.
Shares are the percentage of the 92 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Inertial Confinement Fusion Fusion Technology with Eureka
This page is one run against one query. Ask Eureka your own question about inertial confinement fusion fusion technology and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records anchor the field
Asymmetric capsule for inertial confinement fusion (US20200327998A1)
The patent describes fixing a substantially spherical target capsule containing ICF fuel in position, then applying an oscillatory compression: radial compression orthogonal to a diametric axis at a first time, followed by axial compression along that axis at a second time to drive the capsule into an ovoid shape, which is then further driven to implosion at a third time.Filed by Lawrence Livermore National Security, LLC and published 2020-10-15, this record sits squarely in the G21B core and illustrates how capsule-geometry claims are being used to manage implosion symmetry rather than simply increase compression energy.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20080063132A1 | Method and system for controlled fusion reactions | 61 |
| 2 | US5015054A | Apparatus and method for increasing the bandwidth of a laser beam | 30 |
| 3 | US5136599A | Apparatus and method for increasing the bandwidth of a laser beam | 29 |
| 4 | US4328070A | Method for the initiation of fusion reactions for the controlled release of energy | 29 |
| 5 | US4345212A | Efficient optical pulse stacker system | 28 |
| 6 | US9036765B2 | Method and system for inertial confinement fusion reactions | 27 |
| 7 | US20120328066A1 | Single-pass, heavy ion fusion, systems and method for fusion power production and other applications of a lar… | 24 |
| 8 | US4525323A | Ion beam inertial confinement target | 17 |
| 9 | US4224261A | Methods of fabricating microsponge deuterated initiated hydrocarbon polymer target which emit neutrons when i… | 13 |
| 10 | US20180211732A1 | Hybrid indirect-drive/direct-drive target for inertial confinement fusion | 12 |
Citation counts accumulate over time and favour older records; a high count signals influence within this searched corpus, not that the claims are still the ones to watch for new filings.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three signals stand out once the raw counts are put in context: where claim density sits, where citation influence sits, and where filing venues concentrate.
Fusion-reactor claims are the occupied ground
Two-thirds of the dataset sits in the G21B fusion-reactor subclass, meaning core ignition and reactor-configuration claim space is already dense. New filers competing head-on in capsule or reactor-architecture claims are filing into prior art rather than open ground.
Older foundational patents still anchor citation counts
The most-cited record, US20080063132A1, carries 61 citations, well ahead of the next tier around 28-30. Citation leadership here reflects age and foundational breadth more than current relevance — younger, more specific filings have not had time to accumulate comparable counts.
Filing venue is concentrated in the US
Nearly a third of all records were filed at the USPTO, more than double the WIPO PCT count and nearly triple EPO filings. Smaller receiving offices — New Zealand, Israel, Australia — each carry single-digit counts, indicating ICF patenting strategy is still primarily a US-first exercise with selective international coverage.
Co-filing is rare and personal rather than institutional
Only three co-assignee pairs appear across 92 families, and the strongest pair is two individual co-inventors rather than two companies. This is a field of largely independent filers, not one organised around joint-venture patenting.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to inertial confinement fusion fusion technology, with the prior art for and against each one.
Who is filing, and where momentum has stalled
The assignee list is short and, in the most recent year tracked, uniformly quiet — every named organisation and individual assignee in the momentum data shows zero filings in the latest year, consistent with the overall flat-to-declining trend and with publication lag masking the most recent activity.
National laboratory filings have gone quiet in the most recent window
Lawrence Livermore National Security, LLC appears among the recognisable assignees and is the entity behind the representative asymmetric-capsule record, but shows no filings in the latest tracked year — likely a publication-lag effect rather than a real stop.
Individual co-inventors form the densest collaboration cluster
The strongest co-assignee pair in the dataset is two named individuals, not two companies, filing together four times. This suggests parts of the ICF patent record are driven by small independent teams rather than large corporate R&D groups.
Medical and therapeutic assignees form a distinct sub-cluster
Organisations filing under medicinal preparation and therapeutic activity classes represent a separate constituency from the energy-focused fusion labs, repurposing ICF-adjacent capsule or radiation concepts for delivery or treatment applications.
| Assignee | Recent year | YoY |
|---|---|---|
| Advanced Fusion Systems LLC | 0 | — |
| Kaidong Therapeutics (translated) | 0 | — |
| Lawrence Livermore National Security, LLC | 0 | — |
| JACK COLIN | 0 | — |
| BIRNBACH CURTIS A | 0 | — |
| Alcata Systems Inc. (translated) | 0 | — |
| Government of the United States, as represented by the Secretary of Health and Human Services | 0 | — |
| BURKE ROBERT J | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or identifying a filing gap.
Check the capsule-geometry cluster before filing
Asymmetric and non-spherical capsule claims, exemplified by the Lawrence Livermore record, sit in active G21B territory. Any new capsule-geometry filing should be checked against this cluster specifically, not just the G21B subclass as a whole.
Explore capsule claims in EurekaTrack the medical crossover separately
The A61K/A61P sub-cluster behaves like a different field with a different assignee base. Treating it as part of the core energy landscape risks missing therapeutic-specific prior art.
Map the A61K/A61P cluster in EurekaRevisit the trend once 2025-2026 data matures
Publication lag means the most recent one to two years are undercounted. A follow-up pull in twelve months will give a more reliable read on whether the plateau is real or an artefact of timing.
Set a tracking alert in EurekaCommon questions on ICF patenting
Within this dataset, the most-cited record is US20080063132A1, a method and system for controlled fusion reactions, with 61 citations, well ahead of the next tier of patents around 28-30 citations. Several of the next most-cited records relate to laser bandwidth and pulse-stacking optics, reflecting the importance of drive-laser engineering alongside target physics. High citation counts favour older, foundational filings, so they signal historical influence rather than which patents are most relevant to a filing decision today.
Not clearly. Filing activity moved from 5 records in 2017 to a peak of 6 in 2023, with the 2022 midpoint at only 3 — a flat-to-declining pattern rather than sustained growth. Because publication typically lags filing by around eighteen months, the last one to two years in the dataset will understate true activity, so the most recent apparent decline should not be read as certain until later filings publish. Overall, the pattern is one of steady low-volume activity, not an emerging filing race.
The G21B fusion-reactor subclass dominates, covering 62 of the 92 families in this dataset. H05H, covering plasma and particle accelerators, is a distant second at 14 records. A notable secondary cluster spans A61K and A61P, medicinal preparation and therapeutic activity classes, together accounting for 18 records — indicating that capsule or radiation-delivery techniques developed in an ICF context are also being claimed for medical applications.
The densest claim territory is squarely in G21B fusion-reactor concepts, particularly capsule geometry and compression sequencing, so entering there means filing against established prior art. Thinner areas relative to that core include laser bandwidth and pulse-stacking optics tuned specifically for implosion drive, non-spherical capsule geometries beyond the asymmetric designs already claimed, and plasma diagnostics aimed at measuring implosion symmetry. Any of these should still be checked against the specific patents in that sub-area before drafting a first claim, since low volume does not guarantee an open path.
The United States leads by a clear margin with 29 filings, more than double the WIPO PCT count of 13 and nearly triple the 11 filed at the European Patent Office. New Zealand, Israel and Australia each show single-digit filing counts. This concentration suggests that ICF patent strategy is still primarily built around US protection, with international filings used selectively rather than as a matter of course.
Research Inertial Confinement Fusion Fusion Technology in depth with Eureka
Go past this page: query the whole inertial confinement fusion fusion technology corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.